Prime Medicine Posts Q3 Loss, Pro-Forma Cash of $209.5M and Runway Through 2027
PRME sits 46% above its 52-week low of $2.67.
Summary
Prime Medicine reported a $39.0 million Q3 net loss and disclosed pro-forma cash of about $209.5 million including $134.7 million of net offering proceeds, funding operations through 2027.
Key Events · Earnings and Guidance · PRME
-
Q3 Net Loss of $39.0 Million
Net loss was $39.0 million, or $0.22 per share, versus $50.6 million a year earlier; loss from operations was $39.9 million.
-
Pro-Forma Cash of $209.5 Million
Pro-forma cash, equivalents, investments and restricted cash of approximately $209.5 million after the November offering, with runway through 2027.
-
Offering Nets $134.7 Million
The underwritten offering closed with the full greenshoe, raising $143.7 million gross and about $134.7 million net of discounts and expenses.
-
Spending Falls Year Over Year
R&D was $34.1 million versus $44.0 million and G&A $10.0 million versus $11.2 million in the prior-year quarter.
Analysis · PRME · Life Sciences
The Q3 release itself is close to what Reuters already reported — a $39.0 million net loss and $39.9 million operating loss — but the 8-K adds the number that matters most for a company that carried a going-concern warning in its last 10-Q: pro-forma cash of roughly $209.5 million after the $134.7 million net offering proceeds, enough to fund operations through 2027. That removes near-term financing risk and covers the planned PM359 BLA in the first half of 2027 plus initial PM577a and PM647 data in 2027. Spending is also falling, with R&D down to $34.1 million from $44.0 million a year earlier.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PRME was trading at $3.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $705.6M. The 52-week trading range was $2.67 to $5.91. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.